Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · e6a4bb3c-e423-493f-ad11-b9dff1167fd1

levothyroxine sodium

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-05-20
Captured
2026-09-09T23:38:02.384588+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions ( ) , Drug Interactions ( 7.7 ) , and Overdosage ( 10 )] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including Levothyroxine Sodium Tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity ( , 10 ).

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. () Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Full extracted label fields
application numbers
  1. NDA021116
boxed warning exact
  1. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions ( ) , Drug Interactions ( 7.7 ) , and Overdosage ( 10 )] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including Levothyroxine Sodium Tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity ( , 10 ).
brand names
  1. levothyroxine sodium
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
generic names
  1. LEVOTHYROXINE SODIUM
id
e6a4bb3c-e423-493f-ad11-b9dff1167fd1
indications and usage exact
  1. 1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. () Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
indications and usage tables exact
    is original packager
      manufacturer names
      1. Preferred Pharmaceuticals, Inc.
      matched search terms
      1. cancer
      package ndcs
      1. 68788-7759-3
      2. 68788-7759-9
      3. 68788-7759-1
      product ndcs
      1. 68788-7759
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
        record type
        complete_spl_indications_section_candidate
        routes
        1. ORAL
        rxcuis
        1. 966253
        source batch
        file
        /private/tmp/cancer-full-research/indications/raw/labels-00700.json
        meta
        disclaimer
        Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
        last updated
        2026-09-09
        results
        limit
        100
        skip
        700
        total
        830
        sha256
        24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
        url
        https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=700&sort=id%3Aasc
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
        spl effective date
        2026-05-20
        spl effective time
        20260520
        spl set id
        65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
        spl version
        7
        substance names
        1. LEVOTHYROXINE SODIUM
        uniis
        1. 9J765S329G
        verification flags
        1. oncology_keyword_candidate_not_clinically_classified
        2. spl_text_not_verified_identical_to_latest_approved_label
        3. individual_indications_not_split_or_reconciled
        4. not_identified_as_original_packager
        Drugs@FDA application source records
        1. application number
          NDA021116
          payload
          all indexed label documents
          1. Appl No
            021116
            Application Docs Date
            2002-10-24 00:00:00
            Application Docs ID
            36151
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            ORIG
          2. Appl No
            021116
            Application Docs Date
            2006-03-14 00:00:00
            Application Docs ID
            36152
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            6
            Submission Type
            SUPPL
          3. Appl No
            021116
            Application Docs Date
            2017-09-01 00:00:00
            Application Docs ID
            49659
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            13
            Submission Type
            SUPPL
          4. Appl No
            021116
            Application Docs Date
            2019-04-25 00:00:00
            Application Docs ID
            58413
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            17
            Submission Type
            SUPPL
          5. Appl No
            021116
            Application Docs Date
            2023-11-17 00:00:00
            Application Docs ID
            76605
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            27
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            27
            Submission Status
            AP
            Submission Status Date
            2023-11-16 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          2. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            23
            Submission Status
            AP
            Submission Status Date
            2022-04-14 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            21
            Submission Status
            AP
            Submission Status Date
            2021-12-13 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          4. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            17
            Submission Status
            AP
            Submission Status Date
            2019-04-23 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          5. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            16
            Submission Status
            AP
            Submission Status Date
            2016-05-19 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          6. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            4
            Submission No
            14
            Submission Status
            AP
            Submission Status Date
            2015-11-09 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          7. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            13
            Submission Status
            AP
            Submission Status Date
            2017-08-31 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          8. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            12
            Submission Status
            AP
            Submission Status Date
            2015-01-13 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          9. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            6
            Submission Status
            AP
            Submission Status Date
            2006-03-10 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          10. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            4
            Submission No
            4
            Submission Status
            AP
            Submission Status Date
            2004-12-07 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          11. Appl No
            021116
            Review Priority
            STANDARD
            Submission Class Code ID
            15
            Submission No
            1
            Submission Status
            AP
            Submission Status Date
            2002-10-24 00:00:00
            Submission Type
            ORIG
            Submissions Public Notes
          application number
          NDA021116
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2023-11-16
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            021116
            Application Docs Date
            2023-11-17 00:00:00
            Application Docs ID
            76605
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            27
            Submission Type
            SUPPL
          official application record
          Appl No
          021116
          Appl Public Notes
          Appl Type
          NDA
          Sponsor Name
          ALVOGEN
          openfda application present
          true
          products
          1. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            001
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          2. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            002
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          3. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            003
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          4. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            004
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          5. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            005
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          6. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            006
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          7. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            007
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          8. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            008
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          9. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            009
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          10. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            010
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          11. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            011
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription
          12. Active Ingredient
            LEVOTHYROXINE SODIUM
            Appl No
            021116
            Drug Name
            THYRO-TABS
            Form
            TABLET;ORAL
            Product No
            012
            Reference Drug
            1
            Reference Standard
            0
            Strength
            0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
            marketing status
            1. Prescription

        Source passages and status connections

        Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

        Passage 1 · indication intro context
        application numbers
        1. NDA021116
        brand names
        1. levothyroxine sodium
        classification reasons
        1. explicit_positive_indication_predicate
        2. no_tumor_directed_keyword_in_positive_statement
        3. incomplete_colon_led_indication_intro
        clinical review status
        pending
        content role
        indication_intro_context
        context span
        end
        288
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary Thyrotropin (Thyroid-Stimulat
        label id
        e6a4bb3c-e423-493f-ad11-b9dff1167fd1
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-ae673e1576b052ca8905
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. LEVOTHYROXINE SODIUM
        id
        ind-span-460b360bf4082a22fe70
        label id
        e6a4bb3c-e423-493f-ad11-b9dff1167fd1
        positive predicate support span
        end
        83
        end exclusive
        true
        exact text
        are L-thyroxine (T4) indicated
        label id
        e6a4bb3c-e423-493f-ad11-b9dff1167fd1
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
        start
        53
        qualifier mentions
          regulatory links
            schema version
            0.1.0
            source batch sha256
            24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
            source defined aliases
              source span
              end
              88
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for:
              label id
              e6a4bb3c-e423-493f-ad11-b9dff1167fd1
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
              spl effective date
              2026-05-20
              spl set id
              65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
              spl version
              7
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              not_applicable
              Passage 2 · unclassified context
              application numbers
              1. NDA021116
              brand names
              1. levothyroxine sodium
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              446
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
              label id
              e6a4bb3c-e423-493f-ad11-b9dff1167fd1
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
              start
              0
              current approval status
              not_reconciled
              duplicate text group
              dup-a0b5bb88653bac7c9aba
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. LEVOTHYROXINE SODIUM
              id
              ind-span-98deba29391c91b1768e
              label id
              e6a4bb3c-e423-493f-ad11-b9dff1167fd1
              positive predicate support span
              Source null
              qualifier mentions
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                  source defined aliases
                    source span
                    end
                    246
                    end exclusive
                    true
                    exact text
                    • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ()
                    label id
                    e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                    start
                    89
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                    spl effective date
                    2026-05-20
                    spl set id
                    65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                    spl version
                    7
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear
                    Passage 3 · limitation of use
                    application numbers
                    1. NDA021116
                    brand names
                    1. levothyroxine sodium
                    classification reasons
                    1. negative_or_not_established_clause
                    clinical review status
                    pending
                    content role
                    limitation_of_use
                    context span
                    end
                    885
                    end exclusive
                    true
                    exact text
                    blets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. () Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pi
                    label id
                    e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                    start
                    47
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-2102f92d0818e2bca9d3
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. LEVOTHYROXINE SODIUM
                    id
                    ind-span-a6d7393ec5c9cf8378c0
                    label id
                    e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                    positive predicate support span
                    Source null
                    qualifier mentions
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                        source defined aliases
                          source span
                          end
                          685
                          end exclusive
                          true
                          exact text
                          • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. () Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
                          label id
                          e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                          start
                          247
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                          spl effective date
                          2026-05-20
                          spl set id
                          65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                          spl version
                          7
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          not_applicable
                          Passage 4 · positive indication candidate
                          application numbers
                          1. NDA021116
                          brand names
                          1. levothyroxine sodium
                          classification reasons
                          1. explicit_positive_indication_predicate
                          2. no_tumor_directed_keyword_in_positive_statement
                          clinical review status
                          pending
                          content role
                          positive_indication_candidate
                          context span
                          end
                          1082
                          end exclusive
                          true
                          exact text
                          for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-depen
                          label id
                          e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                          start
                          486
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-134debd66b2d93db9cb1
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. LEVOTHYROXINE SODIUM
                          id
                          ind-span-42ff654e0f37791228fb
                          label id
                          e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                          positive predicate support span
                          end
                          743
                          end exclusive
                          true
                          exact text
                          are indicated
                          label id
                          e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                          start
                          730
                          qualifier mentions
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                              source defined aliases
                                source span
                                end
                                882
                                end exclusive
                                true
                                exact text
                                Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
                                label id
                                e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                start
                                686
                                source url
                                https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                                spl effective date
                                2026-05-20
                                spl set id
                                65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                                spl version
                                7
                                structured fields status
                                not_extracted_no_values_inferred_from_mentions
                                structured indication
                                age
                                Source null
                                approval pathway
                                Source null
                                biomarker and test
                                Source null
                                disease stage
                                Source null
                                limitations
                                Source null
                                line
                                Source null
                                prior therapy
                                Source null
                                regimen
                                Source null
                                tumor histology
                                Source null
                                use intent
                                non_oncology_or_unclear_candidate
                                Passage 5 · positive indication candidate
                                application numbers
                                1. NDA021116
                                brand names
                                1. levothyroxine sodium
                                classification reasons
                                1. explicit_positive_indication_predicate
                                2. tumor_or_malignant_hematology_words_in_positive_statement
                                clinical review status
                                pending
                                content role
                                positive_indication_candidate
                                context span
                                end
                                1322
                                end exclusive
                                true
                                exact text
                                s. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benef
                                label id
                                e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                start
                                683
                                current approval status
                                not_reconciled
                                duplicate text group
                                dup-6dd4174093d025447de6
                                extraction review status
                                automated_candidate_pending_source_review
                                generic names
                                1. LEVOTHYROXINE SODIUM
                                id
                                ind-span-81defc183cb4df25b1be
                                label id
                                e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                positive predicate support span
                                end
                                994
                                end exclusive
                                true
                                exact text
                                are indicated
                                label id
                                e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                start
                                981
                                qualifier mentions
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                                    source defined aliases
                                      source span
                                      end
                                      1122
                                      end exclusive
                                      true
                                      exact text
                                      Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
                                      label id
                                      e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                      start
                                      883
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                                      spl effective date
                                      2026-05-20
                                      spl set id
                                      65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                                      spl version
                                      7
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      tumor_directed_candidate
                                      Passage 6 · limitation of use
                                      application numbers
                                      1. NDA021116
                                      brand names
                                      1. levothyroxine sodium
                                      classification reasons
                                      1. limitation_heading
                                      clinical review status
                                      pending
                                      content role
                                      limitation_of_use
                                      context span
                                      end
                                      1342
                                      end exclusive
                                      true
                                      exact text
                                      ng Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatmen
                                      label id
                                      e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                      start
                                      923
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-94d8a4bbc859efcaaa65
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. LEVOTHYROXINE SODIUM
                                      id
                                      ind-span-b69e4160c6e38a226b1d
                                      label id
                                      e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                      positive predicate support span
                                      Source null
                                      qualifier mentions
                                        regulatory links
                                          schema version
                                          0.1.0
                                          source batch sha256
                                          24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                                          source defined aliases
                                            source span
                                            end
                                            1142
                                            end exclusive
                                            true
                                            exact text
                                            Limitations of Use:
                                            label id
                                            e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                            start
                                            1123
                                            source url
                                            https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                                            spl effective date
                                            2026-05-20
                                            spl set id
                                            65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                                            spl version
                                            7
                                            structured fields status
                                            not_extracted_no_values_inferred_from_mentions
                                            structured indication
                                            age
                                            Source null
                                            approval pathway
                                            Source null
                                            biomarker and test
                                            Source null
                                            disease stage
                                            Source null
                                            limitations
                                            Source null
                                            line
                                            Source null
                                            prior therapy
                                            Source null
                                            regimen
                                            Source null
                                            tumor histology
                                            Source null
                                            use intent
                                            not_applicable
                                            Passage 7 · limitation of use
                                            application numbers
                                            1. NDA021116
                                            brand names
                                            1. levothyroxine sodium
                                            classification reasons
                                            1. negative_or_not_established_clause
                                            clinical review status
                                            pending
                                            content role
                                            limitation_of_use
                                            context span
                                            end
                                            1576
                                            end exclusive
                                            true
                                            exact text
                                            pression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
                                            label id
                                            e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                            start
                                            943
                                            current approval status
                                            not_reconciled
                                            duplicate text group
                                            dup-0f2be768adb47939696e
                                            extraction review status
                                            automated_candidate_pending_source_review
                                            generic names
                                            1. LEVOTHYROXINE SODIUM
                                            id
                                            ind-span-fdef767de99e136f8102
                                            label id
                                            e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                            positive predicate support span
                                            Source null
                                            qualifier mentions
                                              regulatory links
                                                schema version
                                                0.1.0
                                                source batch sha256
                                                24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                                                source defined aliases
                                                  source span
                                                  end
                                                  1444
                                                  end exclusive
                                                  true
                                                  exact text
                                                  • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )].
                                                  label id
                                                  e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                                  start
                                                  1143
                                                  source url
                                                  https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                                                  spl effective date
                                                  2026-05-20
                                                  spl set id
                                                  65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                                                  spl version
                                                  7
                                                  structured fields status
                                                  not_extracted_no_values_inferred_from_mentions
                                                  structured indication
                                                  age
                                                  Source null
                                                  approval pathway
                                                  Source null
                                                  biomarker and test
                                                  Source null
                                                  disease stage
                                                  Source null
                                                  limitations
                                                  Source null
                                                  line
                                                  Source null
                                                  prior therapy
                                                  Source null
                                                  regimen
                                                  Source null
                                                  tumor histology
                                                  Source null
                                                  use intent
                                                  not_applicable
                                                  Passage 8 · limitation of use
                                                  application numbers
                                                  1. NDA021116
                                                  brand names
                                                  1. levothyroxine sodium
                                                  classification reasons
                                                  1. negative_or_not_established_clause
                                                  clinical review status
                                                  pending
                                                  content role
                                                  limitation_of_use
                                                  context span
                                                  end
                                                  1576
                                                  end exclusive
                                                  true
                                                  exact text
                                                  c diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
                                                  label id
                                                  e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                                  start
                                                  1245
                                                  current approval status
                                                  not_reconciled
                                                  duplicate text group
                                                  dup-f5fac9e2f37730276085
                                                  extraction review status
                                                  automated_candidate_pending_source_review
                                                  generic names
                                                  1. LEVOTHYROXINE SODIUM
                                                  id
                                                  ind-span-18ffaa6461d49b03e83c
                                                  label id
                                                  e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                                  positive predicate support span
                                                  Source null
                                                  qualifier mentions
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
                                                      source defined aliases
                                                        source span
                                                        end
                                                        1576
                                                        end exclusive
                                                        true
                                                        exact text
                                                        • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
                                                        label id
                                                        e6a4bb3c-e423-493f-ad11-b9dff1167fd1
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        57689926f31b4b509af8bbc3d2eef64c570dad0b3139792e650edf4033145283
                                                        start
                                                        1445
                                                        source url
                                                        https://api.fda.gov/drug/label.json?search=id%3A%22e6a4bb3c-e423-493f-ad11-b9dff1167fd1%22
                                                        spl effective date
                                                        2026-05-20
                                                        spl set id
                                                        65c8b305-8ffb-4aa5-aca1-f4e4ead71a9c
                                                        spl version
                                                        7
                                                        structured fields status
                                                        not_extracted_no_values_inferred_from_mentions
                                                        structured indication
                                                        age
                                                        Source null
                                                        approval pathway
                                                        Source null
                                                        biomarker and test
                                                        Source null
                                                        disease stage
                                                        Source null
                                                        limitations
                                                        Source null
                                                        line
                                                        Source null
                                                        prior therapy
                                                        Source null
                                                        regimen
                                                        Source null
                                                        tumor histology
                                                        Source null
                                                        use intent
                                                        not_applicable

                                                        Preserved source evidence · Not medical advice